Fabry's disease: Otoneurologic findings in twelve members of one family

Annals of Otology, Rhinology and Laryngology

Volumn 115, Issue 6, 2006, Pages 412-418

  Vibert, Dominique ^a   Blaser, Beat ^a   Ozdoba, Christoph ^a   Häusler, Rudolf ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

Fabry's disease; Hearing loss; Magnetic resonance imaging; Meniere's disease; Tinnitus; Vertigo

Indexed keywords

ALPHA GALACTOSIDASE; GLYCOSPHINGOLIPID;

ADOLESCENT; ADULT; AGED; ANHIDROSIS; ARTHRALGIA; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CORNEA DYSTROPHY; DISEASE SEVERITY; DIZZINESS; ENZYME DEFICIENCY; FABRY DISEASE; FEMALE; HEARING LOSS; HEMANGIOKERATOMA; HEMIZYGOSITY; HETEROZYGOSITY; HISTOPATHOLOGY; HUMAN; KIDNEY FAILURE; LIPID METABOLISM; MALE; NERVE CELL; NEUROLOGIC DISEASE; NEUROLOGIC EXAMINATION; PARESTHESIA; PRIORITY JOURNAL; STRIA; SYMPTOMATOLOGY; VASCULAR ENDOTHELIUM; VERTIGO; VESTIBULOCOCHLEAR NERVE; X CHROMOSOME LINKED DISORDER;

EID: 33745007399     PISSN: 00034894     EISSN: None     Source Type: Journal    
DOI: 10.1177/000348940611500603     Document Type: Article

References (25)

1. Fabry J. Ein Beitrag zur Kenntniss der Purpura haemorrhagica nodularis (Purpura papulosa haemorrhagica Hebrae). Arch Dermatol Syphil 1898;43:187-200.
2. Anderson W. A case of "angeio-keratoma." Br J Dermatol 1898;10:113-7.
3. Ruiter M, Pompen AWM. Angiokeratoma corporis diffusum (universale) mit kardiovasorenalem Symptomenkomplex bei 3 Brüder. Arch Dermat Syph 1939;179:165-72.
4. Opitz JM, Stiles FC, Wise D, et al. The genetics of angiokeratoma corporis diffusum (Fabry's disease) and its linkage relations with the Xg locus. Am J Hum Genet 1965;17:325-42.
5. Stoughton RB, Clendenning WE. Angiokeratoma corporis diffusum (Fabry). Arch Dermatol 1959;79:601-2.
6. De Groot WP. Angiokeratoma corporis diffusum Fabry. Dermatologica 1964;128:321-49.
7. Garcin R, Hewitt J, Godlewski S, Laudat P, de Montera H, Emile J. Les aspects neurologiques de l'angiokératose de Fabry. A propos de deux cas. Presse Med 1967;75:435-40.
8. Miyatake T, Ariga T. Sphingoglycolipids in the nervous system in Fabry's disease. J Neurochem 1972;19:1911-6.
9. Bartimmo EE Jr, Guisan M, Moser KM. Pulmonary involvement in Fabry's disease: a reappraisal follow-up of a San Diego kindred and review of literature. Am J Med 1972;53:755-64.
10. Pabico RC, Atanacio BC, McKenna BA, Pamukcoglu T, Yodaiken R. Renal pathologic lesions and functional alterations in a man with Fabry's disease. Am J Med 1973;55:415-25.
11. Onishi A, Dyck PJ. Loss of small peripheral sensory neurons in Fabry disease. Histologic and morphometric evaluation of cutaneous nerves, spiral ganglia, and posterior columns. Arch Neurol 1974;31:120-7.
12. Bird TD, Lagunoff D. Neurological manifestations of Fabry disease in female carriers. Ann Neurol 1978;4:537-40.
13. Blaser B. Otoneurologische Manifestationen bei Morbus Fabry [Thesis]. Berne, Switzerland: Human Medicine Faculty of University of Berne, 2002.
14. Shows TB, Brown JA, Haley LL, Goggin AP, Eddy RL, Byers MG. Assignment of α-galactosidase (α-Gal) to the q22 → qter region of the X chromosome in man. Cytogenet Cell Genet 1978;22:541-4.
15. Morgan SH, Rudge P, Smith SJM, et al. The neurological complications of Anderson-Fabry disease (α-galactosidase A deficiency) - investigation of symptomatic and presymptomatic patients. Q J Med 1990;75:491-507.
16. Garman SC, Garboczi DN. The molecular defect leading to Fabry disease: structure of human α-galactosidase. J Mol Biol 2004;337:319-35.
17. Schachern PA, Shea DA, Paparella MM, Yoon TH. Otologic histopathology of Fabry's disease. Ann Otol Rhinol Laryngol 1989;98:359-63.
18. Mitsias P, Levine SR. Cerebrovascular complications of Fabry's disease. Ann Neurol 1996;40:8-17.
19. MacDermot KD, Holmes A, Miners AH. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males. J Med Genet 2001;38:750-60.
20. Germain DP, Avan P, Chassaing A, Bonfils P. Patients affected with Fabry disease have an increased incidence of progressive hearing loss and sudden deafness: an investigation of twenty-two hemizygous male patients. BMC Med Genet 2002;3:1-10.
21. Conti G, Sergi B. Auditory and vestibular findings in Fabry disease: a study of hemizygous males and heterozygous females. Acta Paediatr Suppl 2003;92(suppl 443):27, 33-7.
22. Hajioff D, Goodwin S, Quiney R, Zuckerman J, MacDermot KD, Mehta A. Hearing improvement in patients with Fabry disease treated with agalsidase alfa. Acta Paediatr Suppl 2003;92(suppl 443):27-30.
23. Lemaire FX, Feenstra L, Huygen PLM, et al. Progressive late-onset sensorineural hearing loss and vestibular impairment with vertigo (DFNA9/COCH): longitudinal analyses in a Belgian family. Otol Neurotol 2003;24:743-8.
24. Khetarpal U. DFNA9 is a progressive audiovestibular dysfunction with a microfibrillar deposit in the inner ear. Laryngoscope 2000;110:1379-84.
25. Hajioff D, Enever Y, Quiney R, Zuckerman J, MacDermot K, Mehta A. Hearing loss in Fabry disease: the effect of agalsidase alfa replacement therapy. J Inherit Metab Dis 2003;26:787-94.